Conference Call Information
Daniel Passeri, President and Chief Executive Officer of Curis, will host a conference call today, October 27, 2011, at 9:00 a.m. EDT, to discuss Curis’ financial results for the quarter, and corporate developments, plans and strategies.
To access the live conference call, please dial (800) 798-2796 from the U.S. or Canada or (617) 614-6204 from other locations, shortly before 9:00 a.m. EDT. The conference ID number is 77610194. The conference call also can be accessed on the Curis website at www.curis.com in the Investors section. A replay will be available approximately two hours after the completion of the call through 12:00 p.m. EDT, Thursday, November 3, 2011. To access the replay, please dial (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference conference ID number 73522626.
About Curis, Inc.Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com. Curis Cautionary Statement: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s timing for clinical trials of CUDC-101 and CUDC-907; Genentech and Roche's planned regulatory submissions for vismodegib; the potential favorable safety and efficacy profile of vismodegib; and the potential benefits of the Company’s internally developed drug candidates. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates", "assumes", "will", "may," "could" or similar expressions. These forward-looking statements involve risks, uncertainties, assumptions and other important factors that may cause actual results to be materially different from those indicated by such forward-looking statements including, among other things: The FDA may reject Genentech's NDA submission for vismodegib if it fails to meet the FDA’s filing requirements. Roche may not make a timely regulatory submission to the EMA, and the EMA may not accept any such submission if it fails to meet the EMA's filing requirements. Genentech and Roche may not demonstrate to the satisfaction of the FDA or any comparable foreign regulatory agency the safety and efficacy profile of vismodegib in the treatment of advanced BCC. Genentech and Roche may fail to meet applicable regulatory standards for approval of vismodegib in other indications. Even if vismodegib receives marketing authorization, its benefit/risk profile may not be widely accepted by the medical community or third party payors. Debiopharm may experience adverse results, delays and/or failures in its licensed development program. Curis may experience adverse results, delays and/or failures in its internal drug development programs. Curis may experience difficulties with: required regulatory approvals; maintaining necessary intellectual property protections; maintaining key collaborations; and obtaining the substantial additional funding required to conduct its business. Curis may experience unplanned cash requirements, and may not receive additional anticipated payments under its collaborations, any of which would shorten the estimated period in which Curis will have cash to fund its operations. Curis may also face other important risks relating to its business, operations, financial condition and future prospects generally that are discussed in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 and other filings that it periodically makes with the Securities and Exchange Commission. In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|Three months ended||Nine months ended|
|September 30,||September 30,|
|Research and development||3,042,251||3,008,594||9,244,800||7,721,140|
|General and administrative||1,921,206||1,998,701||6,196,337||8,205,523|
|Total operating expenses||4,963,457||5,007,295||15,441,137||15,926,663|
|Net (loss) income from operations||(4,816,335||)||(1,764,985||)||(14,767,610||)||(27,385||)|
|Other income (expense), net||609,780||250,186||(1,153,160||)||1,198,864|
|Net (loss) income||$||(4,206,555||)||$||(1,514,799||)||$||(15,920,770||)||$||1,171,479|
|Basic net (loss) income per common share||$||(0.05||)||$||(0.02||)||$||(0.21||)||$||0.02|
|Diluted net (loss) income per common share||$||(0.05||)||$||(0.02||)||$||(0.21||)||$||0.02|
|Basic weighted average common shares outstanding||76,543,074||75,623,465||76,251,709||74,720,168|
|Diluted weighted average common shares outstanding||76,543,074||75,623,465||76,251,709||77,400,608|
|CONDENSED CONSOLIDATED BALANCE SHEETS|
|September 30, 2011||December 31, 2010|
|Cash, cash equivalents and marketable securities||$||28,358,434||$||40,379,818|
|Investments – restricted||235,914||497,004|
|Property and equipment, net||475,469||302,721|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accounts payable, accrued expenses and other liabilities||$||3,621,889||$||3,526,744|
|Total stockholders' equity||32,406,809||45,517,657|
|Total liabilities and stockholders' equity||$||38,868,106||$||50,649,143|
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV